KCNH2 and neoplasm: Moreover, plasmalemmal hERG1/beta1-integrin complexes seem to be specific for tumor cells (Pillozzi and Arcangeli, 2010) which—at least in theory—increases the possibility to develop tumor-specific inhibitors that target hERG1/beta1-integrin complexes.